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Background  
Human epidermal growth factor receptor type 2 (HER2/ErbB2) is a breast cancer associated protein overexpressed in 20% 
of breast cancers, being involved in cell growth regulation, survival and differentiation.1,2 The location of HER2 on the cell 
surface has contributed to its appeal as a tumour-targeted therapy.3 Aptamers, generated from Systematic Evolution of 
Ligands by EXponential Enrichment (SELEX), emerged as potential tool for application in target cancer therapy due to their 
three-dimensional structures that recognize cell surface receptors.4 
Method  
In this study, HER2-aptamers were screened and identified using SELEX technology. After cloning and sequencing, 
aptamers were modelled through m-fold software and posteriorly, the docking simulation was predicted using ZDOCK 
server.5,6 These in silico predictions measured the aptamer-HER2 interactions through a combination of shape 
complementarity and statistical potential terms for scoring. 
Results & Conclusions  
Based on the interaction score, a candidate ssDNA-aptamer (HER2-31; 5´- 
CACGTGCAGGGTGGATAGCAATCTATCCGGTCCCACTGTTCGGTGGTCGC -3’) was selected. Targeted-specificity of the 
selected HER2-31 was validated through cytometry and fluorescence microscopy assays in HER2-positve breast cancer 
cells. Our results indicate that SELEX technology is an efficient method to screen specific protein-bound ssDNA, and 
HER2-31 could be used as an agent in HER2-based diagnosis and targeted therapy. Also, the results provide valuable 
guidelines for the application of docking simulations for the prediction of aptamer-ligand structures, as well as for the 
design of novel features of ligand-aptamer complexes. 
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